Zinc status biomarkers and cardiometabolic risk factors in metabolic syndrome: a case control study

dc.contributor.authorLima, Severina Carla Vieira Cunha
dc.contributor.authorFreitas, Erika Paula Silva
dc.contributor.authorCunha, Aline Tuane Oliveira
dc.contributor.authorAquino, Sephora Louyse Silva
dc.contributor.authorPedrosa, Lucia de Fátima Campos
dc.contributor.authorLima, Josivan Gomes de
dc.contributor.authorAlmeida, Maria das Graças
dc.contributor.authorEvangelista, Karine Cavalcani Maurício Sena
dc.contributor.authorIDhttps://orcid.org/0000-0001-8268-1986
dc.contributor.authorIDhttps://orcid.org/0000-0002-5436-5115
dc.contributor.authorIDhttps://orcid.org/0000-0002-1627-7018
dc.contributor.authorIDhttps://orcid.org/0000-0001-9729-1243
dc.date.accessioned2025-07-01T17:30:04Z
dc.date.available2025-07-01T17:30:04Z
dc.date.issued2017-02-22
dc.description.resumoMetabolic syndrome (MS) involves pathophysiological alterations that might compromise zinc status. The aim of this study was to evaluate zinc status biomarkers and their associations with cardiometabolic factors in patients with MS. Our case control study included 88 patients with MS and 37 controls. We performed clinical and anthropometric assessments and obtained lipid, glycemic, and inflammatory profiles. We also evaluated zinc intake, plasma zinc, erythrocyte zinc, and 24-h urinary zinc excretion. The average zinc intake was significantly lower in the MS group (p < 0.001). Regression models indicated no significant differences in plasma zinc concentration (all p > 0.05) between the two groups. We found significantly higher erythrocyte zinc concentration in the MS group (p < 0.001) independent from co-variable adjustments. Twenty-four hour urinary zinc excretion was significantly higher in the MS group (p = 0.008), and adjustments for age and sex explained 21% of the difference (R2 = 0.21, p < 0.001). There were significant associations between zincuria and fasting blood glucose concentration (r = 0.479), waist circumference (r = 0.253), triglyceride concentration (r = 0.360), glycated hemoglobin concentration (r = 0.250), homeostatic model assessment—insulin resistance (r = 0.223), and high-sensitivity C-reactive protein concentration (r = 0.427) (all p < 0.05) in the MS group. Patients with MS had alterations in zinc metabolism mainly characterized by an increase in erythrocyte zinc and higher zincuria
dc.identifier.citationFREITAS, Erika Paula Silva; CUNHA, Aline Tuane Oliveira; AQUINO, Sephora Louyse Silva; PEDROSA, Lucia de Fátima Campos; LIMA, Severina Carla Vieira Cunha; LIMA, Josivan Gomes de; ALMEIDA, Maria das Graças; EVANGELISTA, Karine Cavalcani Maurício Sena. Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: a case Control Study. Nutrients (Basel), v. 9, p. 175, 22 fev. 2017. DOI: https://doi.org/10.3390/nu9020175. Acesso em:16 jun. 2025.
dc.identifier.urihttps://doi.org/10.3390/nu9020175
dc.identifier.urihttps://repositorio.ufrn.br/handle/123456789/64074
dc.language.isoen_US
dc.publisherNutrients
dc.rightsAttribution 3.0 Brazilen
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/br/
dc.subjectMetabolic syndrome
dc.subjectZinc
dc.subjectBiomarkers
dc.subjectRisk factors
dc.subjectCardiovascular diseases
dc.titleZinc status biomarkers and cardiometabolic risk factors in metabolic syndrome: a case control study
dc.typearticle

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
ZincStatus_Lima_2017.pdf
Tamanho:
735.48 KB
Formato:
Adobe Portable Document Format
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.53 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar